Clinical Trials Logo

Dry Eye Disease clinical trials

View clinical trials related to Dry Eye Disease.

Filter by:

NCT ID: NCT04567329 Completed - Dry Eye Disease Clinical Trials

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

Start date: November 18, 2020
Phase: Phase 3
Study type: Interventional

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

NCT ID: NCT04548427 Completed - Dry Eye Disease Clinical Trials

Study to Evaluate the Efficacy and Safety of CKD-352

Start date: September 22, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of CKD-352 in patients with dry eye disease

NCT ID: NCT04523129 Completed - Dry Eye Disease Clinical Trials

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Start date: December 5, 2020
Phase: Phase 3
Study type: Interventional

The objective of this pivotal trial is to assess the efficacy, safety and tolerability of CyclASol in comparison to the vehicle for the treatment of signs and symptoms of Dry Eye Disease (DED).

NCT ID: NCT04498182 Completed - Dry Eye Disease Clinical Trials

A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

COMET-1
Start date: November 10, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, multicenter, vehicle-controlled, double-masked, randomized study. All subjects enrolled will have dry eye disease. The study consists of Screening and Baseline visits to determine eligibility followed by efficacy assessments at Day 14 (Visit 3), 28 (Visit 4) and 84 (Visit 5 / Study Exit). Safety will be assessed at all study visits. All subjects will be exposed to the Controlled Adverse Environment (CAE®) at the Screening, Baseline, Day 28 and Day 84 visits. Only subjects who qualify based on inclusion/exclusion criteria, will be enrolled in the study and randomized at a 1:1:1 ratio within each site, to receive AR-15512 0.0014%, AR-15512 0.003% or AR-15512 vehicle to be administered as 1 drop in each eye twice daily for 84 days.

NCT ID: NCT04477421 Completed - Dry Eye Disease Clinical Trials

Femtosecond Small Incision Lenticular Extraction in Comparison to Femtosecond Laser Insitu Keratomileusis Regarding Dry Eye Disease

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Comparison of femtosecond small incision lenticule extraction (FS-SMILE) versus Femtosecond laser Insitu Keratomileusis (FS-LASIK) regarding dry eye disease (DED) and corneal sensitivity (CS) after those refractive surgeries.

NCT ID: NCT04362670 Completed - Dry Eye Disease Clinical Trials

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Start date: April 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.

NCT ID: NCT04357795 Completed - Dry Eye Disease Clinical Trials

Effect of Cequaâ„¢ in Subjects With Dry Eye Disease

Start date: June 29, 2020
Phase: Phase 4
Study type: Interventional

This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.

NCT ID: NCT04268069 Completed - Dry Eye Disease Clinical Trials

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Start date: February 14, 2020
Phase: Phase 2
Study type: Interventional

Evaluation of safety and efficacy of PL9643 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT04201574 Completed - Dry Eye Disease Clinical Trials

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Start date: December 16, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease

NCT ID: NCT04139122 Completed - Dry Eye Disease Clinical Trials

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

Start date: October 5, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease